Charles Schwab Investment Management Inc. Purchases 79,846 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Catalyst Pharmaceuticals by 6.4%, acquiring an additional 79,846 shares, bringing their total to 1,326,771 shares worth approximately $32.17 million.
• Brokerage ratings for Catalyst Pharmaceuticals show a shift, with a dropped rating from "strong-buy" to "hold" by Wall Street Zen, while Cantor Fitzgerald upgraded it to "strong-buy."
• Catalyst Pharmaceuticals' stock saw minor fluctuations, opening at $20.25, with a market cap of $2.48 billion and notable institutional ownership representing 79.22% of the shares.

Charles Schwab Investment Management Inc. lifted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 6.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,326,771 shares of the biopharmaceutical company's stock after acquiring an additional 79,846 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.09% of Catalyst Pharmaceuticals worth $32,174,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Park Square Financial Group LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $29,000. Sound Income Strategies LLC bought a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at about $64,000. GAMMA Investing LLC lifted its stake in shares of Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after buying an additional 579 shares during the period. Quarry LP bought a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $104,000. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 57.2% in the first quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company's stock valued at $133,000 after buying an additional 2,002 shares during the period. Institutional investors own 79.22% of the company's stock.

Insiders Place Their Bets

In related news, insider Preethi Sundaram sold 1,600 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the sale, the insider owned 41,081 shares of the company's stock, valued at $1,085,360.02. The trade was a 3.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CPRX. Wall Street Zen cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 9th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Finally, Zacks Research cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $33.20.

Catalyst Pharmaceuticals Trading Up 2.4%

NASDAQ CPRX traded up $0.5050 on Monday, reaching $21.5850. The company's stock had a trading volume of 126,573 shares, compared to its average volume of 1,303,790. The firm has a market cap of $2.64 billion, a PE ratio of 13.09, a price-to-earnings-growth ratio of 0.86 and a beta of 0.70. The business has a 50-day moving average price of $21.29 and a 200 day moving average price of $22.60. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.00 and a 52 week high of $26.58.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.